PaxGenBio Co., Ltd. was established in 2015 as a molecular diagnostics company that develops, manufactures and markets a portfolio of IVD products targeting infectious diseases and cancers.

PaxGenBio applied its proprietary and chimeric technologies that combine techniques for molecular and immune diagnostics. One of its original technologies, MPCR-ULFA that combines multiplex PCR amplification and universal lateral flow assay (ULFA) enables sensitive, specific, fast, affordable and easy nucleic acid tests that are especially appropriate for applications in low resource settings.

Also, we developed fast SARS-CoV-2 real-time RT-PCR kit detecting the novel corona virus, SARS-CoV-2 by using one-step real-time RT-PCR in a single tube (Run time 50 min, Limit of detection (LoD) : 1 copy/µl (5 copies/reaction)).

Currently, we are developing STI 12 MPCR-ULFA Kit, and we will finish its development within 1st half of next year.